インド東部、マユールバンジ地区における5歳未満児のB型肝炎感染状況とワクチン接種率
K Divyashree Bhat1,2, Haimanti Bhattacharya1, Yuvaraj Jayaraman3
1Department of Microbiology & One Health, ICMR- Regional Medical Research Centre, Bhubaneswar, Odisha, India.
Abstract:
Background & objectives Hepatitis B virus (HBV) infection continues to pose a major public health challenge, especially among rural and tribal communities where access to healthcare services is often limited. The present study aimed to assess the status of HBV infection among children between 1 to 5 yr of age and to evaluate vaccination coverage in the Mayurbhanj district of Odisha. Methods A cross-sectional study was conducted among children aged 1-5 yr. Blood samples were tested for Hepatitis B surface antigen (HBsAg), antibody to Hepatitis B surface antigen (anti-HBs) and other serological markers to determine infection status and vaccination coverage. Results HBsAg seropositivity, indicating active HBV infection, was detected in 0.6 per cent [95% confidence interval (CI): 0.3-0.9] of the samples. Similarly, anti-HBc was tested positive in 0.4 per cent (95% CI: 0.2-0.8) of children. The combined prevalence of HBV infection-based on positivity for either HBsAg or anti-HBc-was 0.8 per cent (95% CI: 0.5-1.2). Vaccination data were collected for 2,647 (98.0%) children of which 90.9 per cent received the birth dose of Hepatitis B vaccine. A total of 98.1 per cent received pentavalent 1 (Penta 1), whereas 97.3 per cent and 96.1 per cent of children received Penta 2 and Penta 3. However, 72.6 per cent (1,961) had protective levels of antibody (anti-HBs) above the threshold, signifying adequate immune protection and 27.4 per cent had sub-protective anti-HBs levels (<10 IU/mL), indicating insufficient immunity. Interpretation & conclusions The results of this study highlighted the need for targeted interventions-such as improving timely administration of the birth dose, enhancing follow-up for subsequent doses including digital or paper-based tools, implementing a robust tracking and reminder system to ensure HBV vaccination series and increasing awareness through community-based health education-to strengthen acceptance of HBV vaccination in rural and tribal communities.
さらに関連する動画
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
関連する概念動画
Vaccinations
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
